Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare form of blood cancer that affects the body’s lymphatic system. About 200 people are diagnosed with it every year in the UK, and this year I’m one of them.

Shortly before Christmas I found a grape-sized lump just above my collarbone. A quick visit to my GP resulted in an ultrasound referral. The ultrasound confirmed I had a swollen lymph node in the posterior triangle of my neck.

The NHS duly swung into action and the lump was removed surgically on Friday 24 January. Preliminary biopsy results several weeks later confirmed the presence of lymphoma cells. A follow-on PET-CT scan and consultation with a haematologist this week established my cancer was low-grade and hadn’t spread, meaning I don’t require additional treatment at this stage and will remain under active monitoring with regular medical check-ups for the forseeable future. Whilst everyone's lymphoma is unique, in general NLPHL responds well when treatment (predominantly chemotherapy or radiotherapy) is required.

A few months ago, my knowledge of blood cancer and Hodgkin lymphoma was non-existent. I now know that blood cancer is the fifth most common cancer in the UK with 40,000 people diagnosed annually, however it’s the third biggest cancer killer with 16,000 people dying every year.

Blood Cancer UK is a UK-based charity dedicated to funding research into all blood cancers including leukaemia, lymphoma and myeloma (bone marrow cancer), as well as offering information and support to blood cancer patients like me.

The last few weeks have been a rollercoaster of emotions, undergoing tests, waiting for results as well as learning about lymphoma in general. I'm incredibly grateful that I can continue to live a normal life and will be completing the Surrey Half Marathon and Ultra X Spring Trail Series 50km in the next month to raise funds for Blood Cancer UK. Thank you for making any donation.

Mark

=======

About Blood Cancer UK

We're a community dedicated to beating blood cancer. We do this by funding research and supporting those affected. Since 1960, we've invested over £500 million in blood cancer research, transforming treatments and saving lives. Right now, our community is funding 360 researchers and staff across the UK who are searching for the next breakthrough. The day we will beat blood cancer is now in sight and the researchers are determined to finish the job.